MAP at day 28 of treatment. MAPs in patients treated with corticosteroids plus natalizumab and control patients treated with corticosteroids only. Dashed line indicates MAP = .29 represents the threshold that discriminates between risk of NRM at day 28 of treatment. Solid line indicates median MAP.